Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
52,382,313
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
40,135,840
-
Shares change
-
-1,373,617
-
Total reported value, excl. options
-
$55,389,702
-
Value change
-
-$2,855,488
-
Number of buys
-
49
-
Number of sells
-
30
-
Price
-
$1.38
Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q1 2025
As of 31 Mar 2025 TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) had 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 40,135,840 shares of stock of the company.
Largest 10 holders included Lynx1 Capital Management LP, BVF INC/IL, BlackRock, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, Propel Bio Management, LLC, Checkpoint Capital L.P., Deer Management Co. LLC, and Alphabet Inc..
This table shows 92 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.